BTG Plc has raised its revenue forecast for the year ended 31 March, in part due to unexpectedly strong sales of the prostate cancer treatment, Zytiga (abiraterone acetate), which is partnered with Johnson & Johnson. ---Subscribe to MedNous to access this article--- Company News
